Kyowa Kirin Co. Ltd. Share Price

Equities

4151

JP3256000005

Pharmaceuticals

Market Closed - Japan Exchange 07:00:00 19/06/2024 BST 5-day change 1st Jan Change
2,680 JPY +1.11% Intraday chart for Kyowa Kirin Co. Ltd. -1.72% +13.06%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 473B 3B 236B Sales 2025 * 485B 3.07B 241B Capitalization 1,419B 8.98B 706B
Net income 2024 * 66.65B 422M 33.17B Net income 2025 * 72.49B 459M 36.08B EV / Sales 2024 * 2.31 x
Net cash position 2024 * 328B 2.07B 163B Net cash position 2025 * 360B 2.28B 179B EV / Sales 2025 * 2.18 x
P/E ratio 2024 *
21.3 x
P/E ratio 2025 *
19.6 x
Employees 5,974
Yield 2024 *
2.19%
Yield 2025 *
2.29%
Free-Float 45.41%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.11%
1 week-1.72%
Current month+0.90%
1 month+2.56%
3 months-7.11%
6 months+12.18%
Current year+13.06%
More quotes
1 week
2 629.50
Extreme 2629.5
2 769.00
1 month
2 536.00
Extreme 2536
2 769.00
Current year
2 266.50
Extreme 2266.5
3 009.00
1 year
2 266.50
Extreme 2266.5
3 009.00
3 years
2 266.50
Extreme 2266.5
4 240.00
5 years
1 674.00
Extreme 1674
4 240.00
10 years
1 094.00
Extreme 1094
4 240.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 31/03/86
President 64 31/03/85
Chief Tech/Sci/R&D Officer 62 31/03/10
Members of the board TitleAgeSince
Director/Board Member 68 28/02/21
Director/Board Member 69 28/02/22
Director/Board Member 66 30/09/08
More insiders
Date Price Change Volume
19/06/24 2,680 +1.11% 1 431 500
18/06/24 2,650 -2.48% 1,424,700
17/06/24 2,718 -1.09% 1,072,700
14/06/24 2,748 +2.29% 2,426,300
13/06/24 2,686 -0.26% 702,800

Delayed Quote Japan Exchange, June 19, 2024 at 07:00 am

More quotes
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows: - sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment; - sales of licenses (7.4%). At the end of 2021, the group had 3 production sites located in Japan (2) and China. Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,680 JPY
Average target price
3,054 JPY
Spread / Average Target
+13.98%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW